Antimicrobial Stewardship

This week, US measles totals reached 1,454, a 750-plus-day SARS-CoV-2 infection in a person with HIV informed care, implementation science efforts advanced access, and a universal flu adjuvant showed promise.

41 cases of nongroupable N meningitidis conjunctivitis were identified at Joint Base San Antonio-Lackland, highlighting diagnostic, treatment, and surveillance implications for congregate living settings.

From COVID-19 antivirals to RSV, influenza, malaria, and gram-negative infections, new research highlights both advances and ongoing challenges in infectious disease prevention and treatment.

In the midst of many changes surrounding aminoglycosides over the past several years, clinicians may be left wondering if these agents still have a role in modern clinical practice. This article summarizes changes impacting aminoglycosides, discusses where these agents may still have a role in the context of gram-negative infections, and explores future areas of study.

Compared to culture/sensitivity results (C/S) results, ICU-based PCR testing of hospital-acquired pneumonia was associated with lower treatment costs and better antibiotic stewardship, but not higher cure rates.

Iterum Therapeutics has launched its sulopenem etzadroxil and probenecid (Orlynvah), which is the first and only oral penem antibiotic in the US.

Ciprofloxacin monotherapy was non-inferior to aminoglycoside/ciprofloxacin combination for bubonic plague in multi-year trial in endemic region.

A 9-month pilot study showed a 55% reduction in resident colonization with MRSA, VRE, and ESBL, but contamination of high-touch surfaces persisted in rooms of MDRO carriers.

The NARROWS framework, developed within the IDSA Core Antimicrobial Stewardship Curriculum, provides a structured, behaviorally informed approach to communication that helps stewardship teams address the social, emotional, and cultural factors influencing prescribing decisions in order to optimize antimicrobial use and combat resistance.

Stenotrophomonas maltophilia is an opportunistic, multidrug-resistant pathogen that poses significant treatment challenges due to its complex resistance mechanisms, limited therapeutic options, and high mortality rates among vulnerable patients.

Clinical trial and real-world data, including the PROVE study, support its role as an effective and carbapenem-sparing therapy for serious infections, though outcomes vary depending on pathogen and infection type.

Doxycycline postexposure prophylaxis is associated with emerging tetracycline resistance in Neisseria gonorrhoeae and commensal organisms, highlighting the need for cautious, targeted use.

A recent literature review describes the current state of artificial intelligence tools for guiding antimicrobial therapy. Are you ready for change?

If this GSK antibiotic is approved, it will provide a new oral option to patients in the US who are currently relying on injectable treatments.

A multi-prong approach reduces inappropriate antibiotic prescribing to outpatients with upper respiratory tract infection.

Clarametyx Biosciences said its investigational antibody therapy, CMTX-101, which is in a phase 1b/2a study, remains on track for full trial enrollment by the end of 2025.

This week, individualized training in high-volume transplant care, reassuring data on aluminum vaccine safety, smarter antibiotic stewardship, and more.

Can duration of therapy requirements at the time of antibiotic order entry decrease antibiotic use?

In the second part of her interview, Temple’s Stephanie Spivack, MD, talks about how she works with different specialties at the hospital to help this marginalized population receive the care they need.

From predicting viral outbreaks via fungal spores and combating drug-resistant gonorrhea to advancing fungal detection through genomic sequencing and improving antiviral resistance testing for vulnerable patients, and more.

Cases and deaths in the state are down from the 2 previous years. Here are some clinical considerations, treatment options, and prevention strategies in relation to these infections.

New evidence-based recommendations prioritize timely, targeted therapy and a symptom-focused classification to optimize treatment outcomes and antimicrobial stewardship.

Analysis by Carly Ching, PhD, reveals that global AMR policies overemphasize human health while neglecting farmer-focused messaging that could improve adoption and impact.

TAXIS Pharmaceuticals Chief Scientific Officer Ajit Parhi, PhD, discusses dihydrofolate reductase inhibitors as a novel approach to combat resistant Neisseria gonorrhoeae.